wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q42136459-4D9601A1-9526-47DE-8E4D-D2A82C424645
Q42136459-4D9601A1-9526-47DE-8E4D-D2A82C424645
BestRank
Statement
http://www.wikidata.org/entity/statement/Q42136459-4D9601A1-9526-47DE-8E4D-D2A82C424645
Incidence and risk factors of retreatment after three-monthly aflibercept therapy for exudative age-related macular degeneration.
P2860
Q42136459-4D9601A1-9526-47DE-8E4D-D2A82C424645
BestRank
Statement
http://www.wikidata.org/entity/statement/Q42136459-4D9601A1-9526-47DE-8E4D-D2A82C424645
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
0642175b106a55ce5e446f29bca5415790534473
P2860
Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.